Stay updated on Venetoclax Regimen to Prevent AML Relapse Clinical Trial
Sign up to get notified when there's something new on the Venetoclax Regimen to Prevent AML Relapse Clinical Trial page.

Latest updates to the Venetoclax Regimen to Prevent AML Relapse Clinical Trial page
- Check5 days agoChange DetectedLatest version shows the study status updated to Terminated and notes that the research center conducted a more comprehensive study. It also adds new sections (Contacts/Locations, Study Design, Study Status, Study Identification, Recruitment Status) and removes the previous 'Recruiting' status along with the location 'Institute of Hematology & Blood Diseases Hospital, China'.SummaryDifference2%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedFooter now displays Revision: v3.3.2, replacing Revision: v3.2.0; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check26 days agoChange DetectedRemoved the general notice about government funding and NIH operating status from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check41 days agoChange DetectedThe record history shows only the earliest version with no recorded changes. The screenshots appear identical, indicating no updates to core content.SummaryDifference0.1%

- Check69 days agoChange Detected- Removed version v3.1.0 and added notice about government funding lapse and current NIH Clinical Center status with links, plus new version tag v3.2.0. Overall, the page now communicates current operating status and a newer version rather than the old one.SummaryDifference13%

- Check76 days agoChange DetectedChanged the revision from v3.0.2 to v3.1.0, indicating a minor version update with no other content changes.SummaryDifference0.3%

Stay in the know with updates to Venetoclax Regimen to Prevent AML Relapse Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Venetoclax Regimen to Prevent AML Relapse Clinical Trial page.